---
title: "Apomorphine Nasal Powder in the Treatment of Parkinson's Disease \"Off\" Periods."
nct_id: NCT00346827
overall_status: COMPLETED
phase: PHASE2, PHASE3
sponsor: Britannia Pharmaceuticals Ltd.
study_type: INTERVENTIONAL
primary_condition: "Parkinson's Disease"
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00346827.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00346827"
ct_last_update_post_date: 2019-07-10
last_seen_at: "2026-05-12T06:16:39.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.

**NCT ID:** [NCT00346827](https://clinicaltrials.gov/study/NCT00346827)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE2, PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 36
- **Lead Sponsor:** Britannia Pharmaceuticals Ltd.
- **Conditions:** Parkinson's Disease
- **Start Date:** 2006-07
- **Completion Date:** 2007-08
- **CT.gov Last Update:** 2019-07-10

## Brief Summary

To determine the safety and tolerability of repeated dosing with Apomorphine Nasal Powder in subjects with Parkinson's Disease.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 85 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* 1 year history of Parkinson's Disease; stable PD medications for 4 weeks; at least one documented "off" period per day

Exclusion Criteria:

* hypersensitivity to apomorphine; participation in a clinical trial in the last 12 weeks; pregnant or lactating females
```

## Interventions

- **Apomorphine Nasal Powder** (DRUG)

## Recent Field Changes (last 30 days)

- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00346827.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00346827*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*